Historical Valuation
Eli Lilly and Co (LLY) is now in the Fair zone, suggesting that its current forward PE ratio of 34.51 is considered Fairly compared with the five-year average of 40.46. The fair price of Eli Lilly and Co (LLY) is between 930.93 to 1507.97 according to relative valuation methord.
Relative Value
Fair Zone
930.93-1507.97
Current Price：1077.19
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Eli Lilly and Co (LLY) has a current Price-to-Book (P/B) ratio of 40.68. Compared to its 3-year average P/B ratio of 46.20 , the current P/B ratio is approximately -11.95% higher. Relative to its 5-year average P/B ratio of 39.75, the current P/B ratio is about 2.34% higher. Eli Lilly and Co (LLY) has a Forward Free Cash Flow (FCF) yield of approximately 0.96%. Compared to its 3-year average FCF yield of 0.60%, the current FCF yield is approximately 59.93% lower. Relative to its 5-year average FCF yield of 1.38% , the current FCF yield is about -30.44% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for LLY competitors is 7.02, providing a benchmark for relative valuation. Eli Lilly and Co Corp (LLY.N) exhibits a P/S ratio of 13.21, which is 88.17% above the industry average. Given its robust revenue growth of 53.87%, this premium appears sustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of LLY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LLY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LLY currently overvalued or undervalued?
Eli Lilly and Co (LLY) is now in the Fair zone, suggesting that its current forward PE ratio of 34.51 is considered Fairly compared with the five-year average of 40.46. The fair price of Eli Lilly and Co (LLY) is between 930.93 to 1507.97 according to relative valuation methord.
What is Eli Lilly and Co (LLY) fair value?
LLY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Eli Lilly and Co (LLY) is between 930.93 to 1507.97 according to relative valuation methord.
How does LLY's valuation metrics compare to the industry average?
The average P/S ratio for LLY's competitors is 7.02, providing a benchmark for relative valuation. Eli Lilly and Co Corp (LLY) exhibits a P/S ratio of 13.21, which is 88.17% above the industry average. Given its robust revenue growth of 53.87%, this premium appears sustainable.
What is the current P/B ratio for Eli Lilly and Co (LLY) as of Jan 14 2026?
As of Jan 14 2026, Eli Lilly and Co (LLY) has a P/B ratio of 40.68. This indicates that the market values LLY at 40.68 times its book value.
What is the current FCF Yield for Eli Lilly and Co (LLY) as of Jan 14 2026?
As of Jan 14 2026, Eli Lilly and Co (LLY) has a FCF Yield of 0.96%. This means that for every dollar of Eli Lilly and Co’s market capitalization, the company generates 0.96 cents in free cash flow.
What is the current Forward P/E ratio for Eli Lilly and Co (LLY) as of Jan 14 2026?
As of Jan 14 2026, Eli Lilly and Co (LLY) has a Forward P/E ratio of 34.51. This means the market is willing to pay $34.51 for every dollar of Eli Lilly and Co’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Eli Lilly and Co (LLY) as of Jan 14 2026?
As of Jan 14 2026, Eli Lilly and Co (LLY) has a Forward P/S ratio of 13.21. This means the market is valuing LLY at $13.21 for every dollar of expected revenue over the next 12 months.